MA32558B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA32558B1
MA32558B1 MA33609A MA33609A MA32558B1 MA 32558 B1 MA32558 B1 MA 32558B1 MA 33609 A MA33609 A MA 33609A MA 33609 A MA33609 A MA 33609A MA 32558 B1 MA32558 B1 MA 32558B1
Authority
MA
Morocco
Prior art keywords
disorders
organic compounds
compounds
treatment
dgat1
Prior art date
Application number
MA33609A
Other languages
Arabic (ar)
English (en)
Inventor
Young-Shin Kwak
Katsumasa Nakajima
Cornelia Jutta Forster
Bing Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41136646&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32558(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32558B1 publication Critical patent/MA32558B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de la formule (i) : dans laquelle a représente un groupe hétéroaryle éventuellement substitué, utile pour le traitement de troubles médiés par l'acyl-coa : diacylglycérol acyltransférase 1 (dgat1), par ex., de troubles métaboliques. L'invention concerne également des méthodes de traitement de tels troubles, ainsi que des composés et des compositions, etc., pour leur traitement.
MA33609A 2008-07-15 2011-02-11 Composes organiques MA32558B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8091308P 2008-07-15 2008-07-15
PCT/EP2009/058960 WO2010007046A2 (fr) 2008-07-15 2009-07-14 Composés organiques

Publications (1)

Publication Number Publication Date
MA32558B1 true MA32558B1 (fr) 2011-08-01

Family

ID=41136646

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33609A MA32558B1 (fr) 2008-07-15 2011-02-11 Composes organiques

Country Status (23)

Country Link
US (1) US8703761B2 (fr)
EP (4) EP2548618A3 (fr)
JP (1) JP5401544B2 (fr)
KR (1) KR20110028661A (fr)
CN (1) CN102119047B (fr)
AR (1) AR072559A1 (fr)
AU (1) AU2009272826A1 (fr)
BR (1) BRPI0916216A2 (fr)
CA (1) CA2731097A1 (fr)
CL (1) CL2011000087A1 (fr)
CO (1) CO6341581A2 (fr)
CR (1) CR20110013A (fr)
EA (1) EA201100189A1 (fr)
EC (1) ECSP11010830A (fr)
IL (1) IL210292A0 (fr)
MA (1) MA32558B1 (fr)
MX (1) MX2011000628A (fr)
NZ (1) NZ590285A (fr)
PE (1) PE20110105A1 (fr)
SV (1) SV2011003809A (fr)
TW (1) TW201006832A (fr)
UY (1) UY31986A (fr)
WO (1) WO2010007046A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
EP2334651A2 (fr) * 2008-07-24 2011-06-22 Theravance, Inc. Agents anti-hypertensifs à double action
WO2010095766A1 (fr) * 2009-02-17 2010-08-26 Banyu Pharmaceutical Co.,Ltd. Dérivés de 1,4-benzodiazépine-2-on
WO2014054053A1 (fr) * 2012-10-03 2014-04-10 Advinus Therapeutics Limited Composés spirocycliques et leurs compositions et applications médicinales
WO2017007755A1 (fr) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
TWI691486B (zh) 2016-01-29 2020-04-21 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途
MD3570834T2 (ro) 2017-01-11 2022-04-30 Alkermes Inc Inhibitori biciclici ai histon deacetilazei
KR20200033224A (ko) 2017-07-27 2020-03-27 도레이 카부시키가이샤 원형 탈모증의 치료제 또는 예방제
WO2019032528A1 (fr) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc Inhibiteurs bicycliques d'histone désacétylase
CN112153984A (zh) * 2018-01-30 2020-12-29 福宏治疗公司 化合物及其用途
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
WO2019194207A1 (fr) 2018-04-04 2019-10-10 日本たばこ産業株式会社 Composé de pyrazole substitué par hétéroaryle et son utilisation médicinale
WO2020113094A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
WO2021155316A1 (fr) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Composés et leurs utilisations
AU2021213258B2 (en) * 2020-01-29 2024-05-02 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4214200A1 (fr) 2020-10-22 2023-07-26 Nimmune Biopharma, Inc. Ligands lancl
TWD226927S (zh) 2022-09-21 2023-08-11 精誠軟體服務股份有限公司 電腦程式之具變化外觀之圖形化使用者介面
TWD226926S (zh) 2022-09-21 2023-08-11 精誠軟體服務股份有限公司 電腦程式之具變化外觀之圖形化使用者介面
WO2024191268A1 (fr) * 2023-03-15 2024-09-19 현대약품 주식회사 Nouveau composé et composition pharmaceutique le comprenant

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526938A (en) * 1974-12-19 1978-10-04 Shell Int Research Derivatives of n-phenyl-n-aroylalanine and herbicidal compositions containing them
CA1160234A (fr) * 1980-10-30 1984-01-10 Masahiko Nagakura Derives de thiadiazole, et methode de preparation connexe
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
US5952294A (en) * 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
AU6229699A (en) * 1998-10-26 2000-05-15 Sumitomo Pharmaceuticals Company, Limited Beta-amyloid formation inhibitors
AU2847200A (en) 1999-01-27 2000-08-18 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
BR0107532A (pt) 2000-04-03 2004-11-03 Bristol Myers Squibb Pharma Co Composto, uso do composto, método para o tratamento de disfunções neurológicas associadas com a produção de b-amilóide, método de inibição da atividade de y-secretase e composição farmacêutica
EP1335914A1 (fr) * 2000-10-26 2003-08-20 Sanofi-Synthelabo Derives de triazole et compositions pharmaceutiques les comprenant
US6841566B2 (en) * 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP2335700A1 (fr) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
JP4164645B2 (ja) * 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
BR0314611A (pt) * 2002-10-09 2005-07-26 Pfizer Prod Inc Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BR0315158A (pt) * 2002-10-09 2005-08-16 Pfizer Prod Inc Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
JP4629657B2 (ja) * 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
PT1638963E (pt) 2003-05-20 2009-11-18 Novartis Ag Heterociclos de azoto n-acilado como ligandos de receptores activados pelo proliferador peroxissomal
JP2005206492A (ja) * 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
KR20070002081A (ko) * 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌
EP1735275B1 (fr) 2004-04-14 2010-08-18 Amgen Inc. Sulfones d'aryle et utilisations liées à eux
JP2006089485A (ja) * 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006033434A1 (fr) 2004-09-24 2006-03-30 Midori Anzen Co., Ltd. Semelle et chaussure
DE102004047840A1 (de) * 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
FR2876692B1 (fr) * 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
TW200843761A (en) * 2004-10-28 2008-11-16 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
WO2006082952A1 (fr) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited Composé amide
CA2607121A1 (fr) * 2005-05-10 2006-11-16 Christophe Michoud Inhibiteurs de diacylglycerol acyltransferase
CA2609203A1 (fr) 2005-05-23 2006-11-30 Merck & Co., Inc Antagonistes des recepteurs d'orexine a base de bis-amide de proline
AR055203A1 (es) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
BRPI0619052A2 (pt) * 2005-11-28 2011-09-20 Hoffmann La Roche compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de diacilglicerol aciltransferase, e seu uso
JP2010523466A (ja) * 2006-04-13 2010-07-15 グラクソ グループ リミテッド 成長ホルモン分泌促進因子受容体アゴニストとしてのアリールおよびヘテロアリールスルホンアミド類
EP2044055A4 (fr) 2006-07-21 2011-03-23 Takeda Pharmaceutical Composés amidés
TW200827340A (en) 2006-11-10 2008-07-01 Astrazeneca Ab Chemical compounds
JP2008133218A (ja) 2006-11-28 2008-06-12 Hokko Chem Ind Co Ltd フェノキシ酪酸アミド誘導体および除草剤
EP2265585B1 (fr) * 2008-02-21 2014-09-17 Boehringer Ingelheim International GmbH Composés amine et éther qui modulent le récepteur cb2

Also Published As

Publication number Publication date
SV2011003809A (es) 2011-07-05
EP2380631A1 (fr) 2011-10-26
US8703761B2 (en) 2014-04-22
WO2010007046A3 (fr) 2010-07-22
US20100022513A1 (en) 2010-01-28
JP5401544B2 (ja) 2014-01-29
TW201006832A (en) 2010-02-16
EP2349484A2 (fr) 2011-08-03
AR072559A1 (es) 2010-09-08
EP2559455A1 (fr) 2013-02-20
CN102119047B (zh) 2014-09-24
PE20110105A1 (es) 2011-02-25
CA2731097A1 (fr) 2010-01-21
CO6341581A2 (es) 2011-11-21
UY31986A (es) 2010-02-26
WO2010007046A2 (fr) 2010-01-21
ECSP11010830A (es) 2011-03-31
IL210292A0 (en) 2011-03-31
EP2548618A2 (fr) 2013-01-23
CR20110013A (es) 2011-02-11
MX2011000628A (es) 2011-02-25
JP2011528016A (ja) 2011-11-10
NZ590285A (en) 2012-10-26
BRPI0916216A2 (pt) 2018-03-13
KR20110028661A (ko) 2011-03-21
EP2548618A3 (fr) 2013-02-27
CL2011000087A1 (es) 2011-07-01
EA201100189A1 (ru) 2011-08-30
CN102119047A (zh) 2011-07-06
AU2009272826A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
MA32558B1 (fr) Composes organiques
MA34235B1 (fr) Composes chimiques
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA29688B1 (fr) Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine
EP2289891A3 (fr) Nouveaux dérivés de polyquinoléines et leur utilisation thérapeutique.
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MA37886A1 (fr) Nouvelles pyridinones bicycliques
GEP20146169B (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
MA33238B1 (fr) Composés utilisés comme antagonistes de la bradykinine b1
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
MA34839B1 (fr) Dihydrofuranes condensés en tant que modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles apparentes
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA35444B1 (fr) Ligands du récepteur ep1
MA35184B1 (fr) Antagonistes de trpv4
MA31080B1 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5.
MX2011007952A (es) Tricianoboratos novedosos.
MA34384B1 (fr) Composés hétérocycliques, leur préparation et leur application thérapeutique
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine